Dr. Thomas Grub has over 16 years of experience in the pharmaceutical industry, specializing in Global Pricing & Market Access. He currently serves as the Director of Global Pricing & Market Access at medac GmbH, where he has been leading the global strategy for market access, pricing, and health economics since September 2024. Prior to this role, he was the Senior Expert for Global Market Access and Health Economics at medac, where he played a pivotal role in developing global access strategies for a diverse range of therapeutic areas, including orphan drugs and immunotherapies.

Earlier in his career, Dr. Grub worked as Director of Global Market Access and Health Economics, where he built and led the Market Access function within the newly established corporate management division at medac. He has also held various roles in the pharmaceutical industry, including Senior Product Manager in dermatology at Schering Deutschland GmbH.

In addition to his corporate roles, Dr. Grub is actively involved in industry associations. He is the Vice Chair of the Value Added Medicines Sector Group of Medicines for Europe and represents EUCOPE in the WHO Europe Novel Medicines Platform.

Dr. Grub holds a Ph.D. in Chemistry from Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau.

Experienced leader with a demonstrated history of 18 years in different areas of pharmaceuticals industry on local, regional and global level, experienced both in Big Pharma and Biotech, skilled in Market Access, Pricing, Medical Affairs and Real Word Evidence with special focus areas of clinical trials, healthcare and reimbursement systems, and Innovative Access Schemes.

Life science expert with +20 years experience in healthcare and pharmaceutical industry including Research and Development, Business Development and Management Consulting. Broad experience from +100 consulting engagements within Strategy, Healthcare Data, Health Economics and Outcomes Research (HEOR), Real-World Evidence (RWE), Payer Evidence Generation, Tendering, Pharmaceutical Pricing and Reimbursement (P&R), Market Access, Value Demonstration, and Governmental Policy in Healthcare and Pharmaceuticals.

At medac group, we believe that health is humanity’s most valuable resource. Since 1970, our mission has been to improve patients’ quality of life worldwide by making the best medical treatments available. As a globally operating pharmaceutical company headquartered in Germany, we provide high-quality medical treatments for patients worldwide in 91 countries. With more than 2.000 employees we are committed to improving human health.   All our products are manufactured in Germany and other European countries to the highest standards, utilizing our own logistics center and production sites, and subsequently distributed worldwide.  

For over 30 years, Miltenyi Biotec has been a major provider of products and services that drive biomedical research and boost cell and gene therapy. More than 4,700 employees in 23 countries combine excellence in research with innovative products to create cutting-edge solutions that make cancer and other disease history. Our expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. At Miltenyi Biotec, scientists, engineers, software developers and many other professionals work together to improve human health by providing smarter cellular technology solutions to researchers and clinicians worldwide.

Every day across Europe, Otsuka-people channel their passion and commitment into aiming to improve the health of our patients. Together we are focusing on some of the world’s unresolved health issues and creating solutions and opportunities for some of the most challenging conditions of the body and mind. We aim to innovate with integrity and are committed to conducting business ethically and in compliance with the laws and regulations of the countries where we operate. Our ultimate goal is to help people live healthier lives.